Skip to main
  1. Stocks
  2. Monopar Therapeutics
  3. Forecast
MNPR

Monopar Therapeutics (MNPR) Stock Forecast & Price Target

Monopar Therapeutics (MNPR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Monopar Therapeutics is viewed favorably because ALXN1840 has a compelling regulatory profile, with positive Phase 3 efficacy data, long-term safety findings, and analyses suggesting copper is being effectively excreted rather than redistributed. The rolling NDA submission initiated in July, together with FDA constructiveness, rare disease guidance, and the potential for a Priority Review Voucher, improves the path to approval while cash of about $129M to $134.3M supports operations through at least March 31, 2028 or YE27. Beyond Wilson disease, the MNPR-101 radiopharmaceutical platform adds optionality in oncology, supporting a substantial unmet-need and commercial opportunity thesis.

Bears say

Monopar Therapeutics is burdened by substantial clinical and regulatory execution risk, as its pipeline remains dependent on proving statistical and clinical benefit in late-stage and early-stage programs such as ALXN1840, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The company also faces a difficult competitive backdrop in Wilson disease, where multiple therapies are already commercialized or in development, potentially limiting adoption even if approval is achieved and making reimbursement and physician switching behavior major obstacles to revenue generation. Given its single-segment, development-stage profile and need for future partnerships or financings, the business remains exposed to dilution, capital constraints, and the possibility that regulatory requirements or negative trial outcomes could derail value creation.

Monopar Therapeutics (MNPR) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Monopar Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Monopar Therapeutics (MNPR) Analyst Forecast & Price Prediction

Get the latest Monopar Therapeutics (MNPR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Monopar Therapeutics (MNPR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Monopar Therapeutics (MNPR) Forecast

Analysts have given Monopar Therapeutics (MNPR) a Buy based on their latest research and market trends.

According to 6 analysts, Monopar Therapeutics (MNPR) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Monopar Therapeutics (MNPR)


Monopar Therapeutics (MNPR) Analyst Forecast & Price Prediction

Get the latest Monopar Therapeutics (MNPR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Monopar Therapeutics (MNPR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MNPR stock data and trends